1682-Gut Metabolites and CAR-T Therapy Outcomes
Research evaluating patients undergoing CAR-T cell therapy reveals that the taxonomic composition of the gut microbiome is a poor indicator of therapeutic success, whereas gut immunomodulatory metabolites strongly influence clinical outcomes. Through metagenomic and metabolomic analyses, investigators discovered that short-chain fatty acids, particularly valeric acid, enhance T-cell function, fitness, and tumor control. Conversely, indole derivatives and branched-chain fatty acids like isovaleric acid impair CAR-T cell efficacy and promote tumor growth. Furthermore, antibiotic exposure prior…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.